LONDON (Thomson Financial) - Taihua PLC said it has initiated correspondence
with the European Directorate for the Quality of Medicines (EDQM) in relation to
an application for a certificate of suitability for its anti-cancer compound
paclitaxel.
The biopharmaceutical company said it has initiated the correspondence
through its appointed Chinese regulatory agents, Beijing Canny.
TFN.newsdesk@thomson.com
kal/slj
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|